Osaka City General Hospital Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2010
NCT01184599
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

aliskiren (tekturna) (1 trial)

dexmedetomidine (precedex) (1 trial)

Drugs in Other Trials (1)

autologous umbilical cord blood (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Sepsis (Phase 4)

Toxemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 3